Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 8c
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.33 -1.84%
Revenue Growth %: +24.1%
Financial Fact:
Intangible asset amortization: 2.94M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +24.1%
Financial Fact:
Intangible asset amortization: 2.94M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of ($0.03), $0.08 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $41.3 million versus the consensus estimate of $43.92 million.
Sees Q4 combined net product sales from both HETLIOZ and Fanapt $42 to $48 million
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- UBS upgrades Lockheed Martin to Buy, sees 26% upside on missile growth
- ABM Industries (ABM) Reports In-Line Q3 EPS; raises guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
